Technology may miss many target binding loci of a transcription factor. Our future studies will focus on conducting ChIP-3C-qPCR to confirm whether these distal binding loci are indeed related to these particular genes, potentially uncovering the underlying mechanism of TGFb/ SMAD4 mediated gene regulation. One important aspect of this study is the use of in silico mining of publicly Ibrutinib inquirer available patient cohort data to identify a subset of TGFb/SMAD4 target genes as a gene signature for predicting clinical outcomes. As far as we know, this is the first study to attempt to use TGFb signaling responsive SMAD4 regulated genes to classify ovarian cancer patients into different sub-types of patient groups, as well as predict poor survival from good survival populations with statistical significance. Thus, combining ChIP-seq identified binding loci, gene expression profiling, and an in silico mining of patient cohorts may provide a powerful approach for identifying potential gene signatures with biological and clinical importance. In conclusion, our study provides the first comprehensive genome-wide map of thousands of TGFb/SMAD4 targets in an ovarian cancer cell line, which could further be used for studying SMAD4 functions in tumorigenesis. To our knowledge, this is the first study to link TGFb/SMAD4 regulated genes to clinical information on ovarian cancer patient survival and identify potential gene signatures for prognosis in ovarian cancer. In our future studies, we will conduct ChIP-seq analysis of TGFb/ SMAD4 binding sites using a panel of ovarian cancer cell lines representing different histological subtypes and ovarian cancer initiating cells. Influenza is a resurging and emerging disease with virtually no possibility of eradicating the causal virus which triggers seasonal as well as pandemic influenza. As a zoonotic disease with the potential to sicken both animals and humans, a designer IFV can be rapidly generated by reverse genetics and disseminated by terrorists to ravage agriculture, public health, and economy within a targeted region. Even though this highly contagious and potentially fatal disease has been partially controlled by vaccination, the licensed influenza vaccine is difficult to mass-produce and unable to confer timely as well as broad protection against heterosubtypic IFV strains. Another line of defense against influenza is the use of influenza drugs ; however, this option is limited by the emergence of drug-resistant IFV due to selection under mutational pressure. To develop a rapid-response anti-influenza agent.